Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 896.

https://doi.org/10.1182/blood-2024-197929

Published: 2024

Journal Articles

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 247.

https://doi.org/10.1182/blood-2024-201288

Published: 2024

Journal Articles

The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma

Praneeth Reddy Sudalagunta, David R. Noyes, Gabriel De Avila, Alexandra Achille, Rafael Renatino-Canevarolo, Xiaohong Zhao, Maria Silva, Angel Perez, Mark B. Meads, Lauren C. Peres, Doris K. Hansen, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2024) 144 (Supplement 1): 4645.

https://doi.org/10.1182/blood-2024-205631

Published: 2024

Journal Articles

Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma

Marios Papadimitriou, Marilena Tauro, Afsaneh Panahi, Bachisio Ziccheddu, Alexandra Maria Poos, Abdessamad Youssfi Alaoui, Dario Magaletti, Mark B. Meads, Kylee H Maclachlan, Marc S. Raab, Gareth Morgan, Saad Z. Usmani, Niels Weinhold, Ola Landgren, Kenneth H. Shain, Florian Kuchenbauer, Francesco Maura

Blood (2024) 144 (Supplement 1): 3276.

https://doi.org/10.1182/blood-2024-211173

Published: 2024

Journal Articles

De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression

Mark B. Meads, Xiaohong Zhao, David R. Noyes, Alexandra Achille, Praneeth Reddy Sudalagunta, Chaomei H. Zhang, Sonila Toska, Jongphil Kim, Samer Sansil, Sean J. Yoder, Ariel Grajales-Cruz, Brandon Blue, Ciara Louise Freeman, Melissa Alsina, Ariosto Siqueira Silva, Xiaofei Song, Rachid Baz, Kenneth H. Shain

Blood (2024) 144 (Supplement 1): 1906.

https://doi.org/10.1182/blood-2024-210232

Published: 2024

Journal Articles

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

Blood (2024) 144 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2024-206353

Published: 2024

Journal Articles

Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease

Ciara Louise L. Freeman, Xiaohong Zhao, Mark B Meads, Jerald Noble, Raghunandan Reddy Alugubelli, Rafael Renatino-Canevarolo, Oliver Hampton, Praneeth Reddy Sudalagunta, Ariosto Siqueira Silva, Rachid Baz, Melissa Alsina, Doris K. Hansen, Xiaofei Song, Kenneth H. Shain

Blood (2023) 142 (Supplement 1): 3304.

https://doi.org/10.1182/blood-2023-191013

Published: 2023

Journal Articles

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2023-190658

Published: 2023

Journal Articles

Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma

Marios Papadimitriou, Marilena Tauro, Bachisio Ziccheddu, Alexandra Maria Poos, Abdessamad Youssfi Alaoui, Mark B Meads, Kylee H Maclachlan, Saad Z Usmani, Marc S. Raab, Gareth J. Morgan, Niels Weinhold, Kenneth H. Shain, Ola Landgren, Francesco Maura

Blood (2023) 142 (Supplement 1): 639.

https://doi.org/10.1182/blood-2023-184784

Published: 2023

Journal Articles

Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies

Blood (2023) 142 (Supplement 1): 4678.

https://doi.org/10.1182/blood-2023-185930

Published: 2023

Journal Articles

Ex Vivo Mathematical Myeloma Advisor (EMMA) - a Clinical, Molecular, and Phenotypic Platform to Tailor Personalized Therapeutic Strategies for Multiple Myeloma

Rafael Renatino-Canevarolo, Maria Silva, Mark B Meads, Xiaohong Zhao, Alexandra Achille, David Noyes, Praneeth Reddy Sudalagunta, Raghunandan Reddy Alugubelli, Daniel Lastorino, Leticia Tordesillas, Miguel Gomez Fontela, Oliver Hampton, Daniel Abate-Daga, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2023) 142 (Supplement 1): 2280.

https://doi.org/10.1182/blood-2023-190479

Published: 2023

Journal Articles

A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data

Praneeth Reddy Sudalagunta, Mark B. Meads, Rafael Renatino-Canevarolo, Maria L. Coelho Siqueira Silva, Xiaohong Zhao, Rhett Waldron, Christopher Cubitt, Raghunandan Reddy Alugubelli, Gabriel De Avila, Oliver Hampton, Robert Gatenby, Rachid C. Baz, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2022) 140 (Supplement 1): 4245–4246.

https://doi.org/10.1182/blood-2022-162454

Published: 2022

Journal Articles

Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes

Rafael Renatino-Canevarolo, Mark B. Meads, Maria L. Coelho Siqueira Silva, Praneeth Reddy Sudalagunta, Christopher Cubitt, Gabriel De Avila, Raghunandan Reddy Alugubelli, Amit Kulkarni, Qi Zhang, Oliver Hampton, Rachid C. Baz, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2022) 140 (Supplement 1): 3036–3037.

https://doi.org/10.1182/blood-2022-163511

Published: 2022

Journal Articles

Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo

Kenneth H. Shain, MD PhD, Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan Reddy Alugubelli, Amit Kulkarni, PhD, Qi Zhang, PhD, Oliver Hampton, Constantine Logothetis, MD, Christian Argueta, PhD, Yosef Landesman, PhD, Ariosto Siqueira Silva, PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140485

Published: 2020

Journal Articles

Dynamic Epigenetic Landscapes Define Multiple Myeloma Progression and Drug Resistance

Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Maria Silva, Praneeth Reddy Sudalagunta, PhD, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan R Alugubelli, MS, Amit Kulkarni, PhD, Qi Zhang, PhD, Oliver Hampton, Kenneth H. Shain, MD PhD, Ariosto Siqueira Silva, PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142872

Published: 2020

Journal Articles

Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma

Ariosto Siqueira Silva, PhD, Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Maria D Coelho Siqueira Silva, MSc, Praneeth Reddy Sudalagunta, PhD, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan Reddy Alugubelli, Amit Kulkarni, PhD, Melissa Mitchell, Hongyue Dai, Qi Zhang, PhD, Oliver Hampton, Xin Lu, Dimple A. Modi, PhD, Monica Motwani, PhD, Jason Harb, PhD, Jeremy A. Ross, Kenneth H. Shain, MD PhD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-134924

Published: 2020

Journal Articles

Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression

Rupal Ramakrishnan, Alexandra Achille, Tuan Nyugen, Ian Taylor, BS, Gabriel De Avila, BS, Raghunandanreddy Alugubelli, MS, Mark B. Meads, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD

Blood (2019) 134 (Supplement_1): 4392.

https://doi.org/10.1182/blood-2019-131966

Published: 2019

Journal Articles

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Rafael Renatino-Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Mark B. Meads, PhD, Alexandre Tungesvik, MD, Gabriel De Avila, Alugubelli Raghunandan Reddy, Minerva Nong, Jamie Teer, PhD, Eric A. Welsh, PhD, Tint Lwin, MD PhD, Amit Kulkarni, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Kenneth H. Shain, MD PhD, Ariosto Siqueira Silva, PhD

Blood (2019) 134 (Supplement_1): 5544.

https://doi.org/10.1182/blood-2019-128442

Published: 2019

Journal Articles

Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 5534.

https://doi.org/10.1182/blood-2019-132001

Published: 2019

Journal Articles

A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma

Karen L Burger, PhD, Mark B. Meads, PhD, Anders Berglund, Paula S. Oliveira, Allison Distler, Praneeth Reddy Sudalagunta, PhD, Timothy Jacobson, Jamie Teer, PhD, Eric A. Welsh, PhD, Hongyue Dai, PhD, John M. Koomen, PhD, Alugubelli Raghunandan Reddy, Gabriel De Avila, Alexandre Tungesvik, MD, William Roush, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD, John Cleveland, PhD

Blood (2019) 134 (Supplement_1): 5537.

https://doi.org/10.1182/blood-2019-130830

Published: 2019

NARROW

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma

Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma

De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma

Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies

Ex Vivo Mathematical Myeloma Advisor (EMMA) - a Clinical, Molecular, and Phenotypic Platform to Tailor Personalized Therapeutic Strategies for Multiple Myeloma

A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data

Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes

Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo

Dynamic Epigenetic Landscapes Define Multiple Myeloma Progression and Drug Resistance

Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma

Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma

A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only